Regeneron, Bayer to co-develop Eylea combination treatment
Send a link to a friend
[January 14, 2014] (Reuters)
Pharmaceuticals Inc. and Germany's Bayer AG said they would
co-develop an antibody for use in combination with Eylea, their
treatment for a form of age-related blindness.
Bayer's unit, Bayer HealthCare, will pay Regeneron
$25.5 million upfront and share global development costs for the
program, the companies said in a joint statement.
Both the Eylea injection and the new combination treatment is to
treat wet age-related macular degeneration (wet AMD) — the leading
cause of blindness in the elderly.
"Given the multi-factorial nature of wet AMD, there is a potential
for additional benefits to patients by addressing different pathways
responsible for this devastating condition", Bayer HealthCare global
development head Kemal Malik said.
Regeneron will hold marketing rights to the drug in the United
States, while Bayer will have rights outside the U.S. The two
companies will split the profits from outside the U.S.
Regeneron is eligible to get up to $40 million in option and
milestone payments once the drug is approved. The drug is expected
to be tested for safety and efficacy early this year.
AMD is a chronic condition that requires visually impaired patients
to make monthly visits to the clinic.
Since its launch in late 2011, Eylea has become one of the
fastest-growing medicines in the history of biotechnology, grabbing
market share from rivals such as Roche AG's Lucentis.
[to top of second column]
Bayer and Regeneron are also collaborating on the development of
Eylea, which is currently being tested for use in diabetic macular
edema (DME) and macular edema following branch retinal vein
Tarrytown, New York-based Regeneron closed at $268.68 on the Nasdaq
(Reporting by Natalie Grover in
Bangalore; editing by Savio D'Souza)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.